Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis.
Takeda Submits a New Drug Application for Glatiramer Acetate in Japan for the Relapse Prevention of Multiple Sclerosis
Lipids and lipid-reactive antibodies as biomarkers for multiple sclerosis.
Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder.
Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML.
IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis.
Application of fullerenes in nanomedicine: an update.
Assessment of Disease Activity in Multiple Sclerosis Phenotypes with Combined Gadolinium- and Superparamagnetic Iron Oxide-enhanced MR Imaging.
Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy.
Disrupted balance of T cells under natalizumab treatment in multiple sclerosis.
Benefit of Endermology on Indurations and Panniculitis/Lipoatrophy During Relapsing-Remitting Multiple Sclerosis Long-Term Treatment with Glatiramer Acetate.
Copolymer 1 inhibits manifestations of graft rejection.
PI(3,5)P2 biosynthesis regulates oligodendrocyte differentiation by intrinsic and extrinsic mechanisms.
Idebenone for primary progressive multiple sclerosis
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.
Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multipl
Company restores access to multiple sclerosis drug after pressure from neurologists.
Varicella-Zoster Virus Infections in Patients Treated With Fingolimod: Risk Assessment and Consensus Recommendations for Management.
No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT.
The mystery of missing heritability: Genetic interactions create phantom heritability.
FTY720 in patients with primary progressive multiple sclerosis (INFORMS)
Ustekinumab.
B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.
Long-Term Cost-Effectiveness Model of Interferon Beta-1b in the Early Treatment of Multiple Sclerosis in the United States.

Pages